Lantheus Omega and related Lantheus entities are reported as beneficial owners of 20.9% of Radiopharm Theranostics’ ordinary shares, based on holdings and options. The position matters to investors because it combines issued stock with Options to purchase 255,000,000 additional shares at AUD $0.039 each, expiring on October 31, 2027.

Key Highlights

  • Lantheus Omega’s position includes 255,000,000 ordinary shares issued on December 9, 2025.
  • Options covering 255,000,000 ordinary shares carry an AUD $0.039 exercise price and expire on October 31, 2027.
  • The ownership percentage is calculated using 3,544,216,160 ordinary shares outstanding as of June 30, 2026, plus the option shares.

Radiopharm Theranostics Ltd (NASDAQ: RADX) has a reported beneficial ownership position of 20.9% linked to Lantheus Omega, Lantheus Medical Imaging and Lantheus Holdings (NASDAQ: LNTH). The percentage represents the aggregate position as of July 27, 2026, including ordinary shares and options tied to the December issuance.

Lantheus Position Includes Shares and Options

Lantheus Omega holds 149,625,180 Radiopharm ordinary shares issued on August 23, 2024, along with 133,333,333 shares issued on January 20, 2025. The entity also received 255,000,000 ordinary shares on December 9, 2025. The reporting entities said they had no current plans or proposals relating to specified corporate actions. They may review or change that position, or develop such plans, at any time.